Arctech Innovation has announced the appointment of Dr Annalisa Jenkins, a biopharma thought leader with over 25 years of industry experience, to its Board of Directors.

Dr Jenkins brings extensive expertise in advancing biotech companies pursuing cures for the most challenging rare diseases to address important medical issues globally. She has a distinguished industry career, including roles as the former head of Global R&D for Merck Serono and Head of Global Medical Affairs for Bristol Myers Squibb. Dr Jenkins is the current chair of the court at the London School of Hygiene and Tropical Medicine, a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and a non-executive director at Genomics England. She also serves on the boards of a number of UK and International private and public life-science, health care and impact focussed companies.

Arctech Innovation is a spin-out company from the London School of Hygiene & Tropical Medicine, combatting the greatest public health threats, including COVID-19  and malaria, by developing, evaluating, and commercialising novel technologies for the surveillance and control of infectious diseases.

“Dr Jenkins has a proven track record in growing both private and public companies in the life sciences industry, and we are delighted to welcome her to our Board,” commented Professor James Logan, Co-founder and CEO of Arctech Innovation. “As we accelerate the development and commercialisation of several game-changing technologies for diseases such as COVID-19, Dr Jenkins’ experience and expertise will be invaluable to our leadership team.”

“I am honoured and excited to join Arctech Innovation’s Board to help it achieve its vision of tackling some of the world’s deadliest diseases by bringing to market an innovative range of odour-based diagnostic and insect control solutions,” added Dr Jenkins.